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More than 600 million people are now obese which is equivalent to 13% of the world population. In 2008, it was predicted that this number of people with obesity would first be reached by year 2030. 1 This much faster increase in the number of people with obesity is especially alarming since central (abdominal) obesity is positively linearly associated with increase in morbidity, especially driven by cardiovascular disease and Type 2 diabetes mellitus, and an at least 30% increased overall mortality rate compared with normal weight. 2 Both people with Type 2 diabetes and obesity have Glucagon-likepeptide-1 (GLP-1) impairment.
3,4 GLP-1 is an intestine hormone that contributes to the amplification of insulin secretion from pancreatic beta cells following food ingestion and thereby lowers blood glucose as well as inhibiting appetite. A decreased level of GLP-1 is observed already in the overweight and pre-diabetes state.
3 GLP-1 receptor agonists are used in the treatment of Type 2 diabetes and obesity and reduce blood glucose levels along with body weight.
New therapeutic options for Type 2 diabetes are required by the US Food and Drug Administration (FDA) to evaluate the cardiovascular risks associated with the drug. Thus, as a request from the FDA several large prospective clinical trials have reported the association between GLP-1 receptor agonists and cardiovascular risks; ELIXA study (lixisenatide), 5 LEADER study (liraglutide), 6 SUSTAIN-6 study (semaglutide), 7 and EXSCEL study (exenatide). 8 ELIXA, LEADER, and SUSTAIN-6 were performed with patients that had Type 2 diabetes as well as a high cardiovascular risks, whereas EXSCEL was performed with Type 2 diabetes patients regardless of cardiovascular risk. The conclusion from all four trials is that GLP-1 receptor agonists are not associated with an increase in cardiovascular events compared with placebo. [5] [6] [7] [8] On the contrary, liraglutide and semaglutide decreased the risk of primary composite endpoint of cardiovascular events by 13% and 26% [hazard ratio 0.87, 95% confidence interval 0.78-0.97; and 0.74 (0.58-0.95)] compared with placebo, respectively. A recent study confirmed that liraglutide and semaglutide decrease the risk of major adverse cardiovascular events compared with placebo when using the difference in restricted mean survival time as a measure of cardiovascular risks. 9 In the EXSCEL study, the direction and magnitude of the cardiovascular outcomes observed were consistent with those seen in the LEADER and SUSTAIN-6 trials but statistical significance for the primary composite outcome was not achieved. 8 This may be due to several points: (i) The follow-up time and duration of exposure was shorter than that in the LEADER trial. (ii) Baseline glycated haemoglobin level was lower than that in the LEADER trial, and the rate of discontinuation was higher. (iii) Importantly, the effect of exenatide, administered once weekly, on modifiable cardiovascular risk factors such as weight lowering was modest when compared with liraglutide and semaglutide and the drugs may not be bioequivalent. (iv) The disproportionate use in the placebo group of diabetes therapies known to reduce cardiovascular risk such as SGLT-2 inhibitors and GLP-1 receptor agonists may have resulted in lower event rates in the placebo group. 6, 8 Semaglutide is currently evaluated as obesity treatment also. A 52 week double-blinded Phase 2 study uses lower, but daily subcutaneous Signe Torekov is Associate Professor and Group Leader at Department of Biomedical Sciences and the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen. She is leading a research group that focuses on clinical metabolic translational research by combining physiology and genetics with treatment in humans with obesity at risk for cardiovascular disease. A major focus is on how to maintain a healthy sustained weight loss. For her work in obesity and metabolic research, she recently received the prestigious Anders Jahre Young Medical Award for outstanding scientific work. 
What role could GLP-1 receptor agonists have in cardioprotection?
Some concerns regarding the effect of GLP-1 receptor agonist on the heart have been raised since increased heart rate is observed and treatment might be contraindicated in individuals with advanced heart failure.
11 However, at the same time blood pressure is reduced which might outweigh the risk in people without heart failure. Furthermore, since both liraglutide and semaglutide reduce development of cardiovascular disease it seems overall safe with respect to cardiovascular risk. 6, 7 In a rat model of myocardial infarction, it was shown the GLP-1 RA exenatide had direct cardioprotective effect, 12 However, increasing evidence indicates that GLP-1 receptor agonists, besides the indirect beneficial effects such as decreasing hyperglycaemia, hypertension and weight, also seem to have several beneficial direct effects on atherosclerosis. Thus, treatment with GLP-1 receptor agonists seems to improve endothelial cell dysfunction in association with a reduction in expression of inflammatory molecules associated with atherogenesis in both human and murine endothelial cells and serum.
Thus, GLP-1 receptor agonists may shift both human and murine monocytes/macrophages towards anti-inflammatory phenotype and reduce the LPS-induced inflammatory response. Finally, a few small human studies have demonstrated direct anti-inflammatory effects of GLP-1 receptor agonists on atherogenesis independent of weight loss. 14, 15 So far the combination of weight loss, reduction of blood glucose, and blood pressure as well as decrease of the risk of major adverse cardiovascular events obtained with liraglutide and semaglutide seems promising. However, developments of more agents, or the combination, that successfully both maintains weight loss and reduces the risk of cardiovascular disease will be beneficial for a more individualized treatment.
Furthermore, as physical activity seems to help prevent development of both obesity, Type 2 diabetes and cardiovascular disease even more focus on integrating physical activity as a treatment in combination with pharmacological treatment is warranted.
